Beam Therapeutics
BEAM
158 hedge funds and large institutions have $3.01B invested in Beam Therapeutics in 2020 Q4 according to their latest regulatory filings, with 80 funds opening new positions, 44 increasing their positions, 8 reducing their positions, and 7 closing their positions.
1,043% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 7
450% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 8
315% more capital invested
Capital invested by funds: $727M → $3.01B (+$2.29B)
86% more funds holding
Funds holding: 85 → 158 (+73)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
6.65% more ownership
Funds ownership: 57.04% → 63.69% (+6.6%)
56% less call options, than puts
Call options by funds: $14.4M | Put options by funds: $32.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$55.6M |
| 2 |
BlackRock
New York
|
+$45.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$44.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.9M |
| 5 |
Goldman Sachs
New York
|
+$26.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$6.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.12M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$1.08M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$706K |
| 5 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$534K |
BEAM Hedge Fund Activity: Q4 2020 in Review
158 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q4 2020, worth a combined $3.01B — up 315% from $727M a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new BEAM positions and 7 closed out — a net gain of 73 holders — while 44 added to existing stakes and 8 trimmed.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $55.6M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $6.5M sold.
- 158 institutional investors held Beam Therapeutics (BEAM) as of Q4 2020, up from 85 in Q3 2020.
- Funds reported $3.01B of Beam Therapeutics stock for Q4 2020, up 315% quarter-over-quarter.
- 80 funds opened new Beam Therapeutics positions in Q4 2020 and 7 closed out, a net change of +73 holders.
- The largest Beam Therapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $55.6M added.
- The largest Beam Therapeutics seller in Q4 2020 was Marshall Wace North America, an estimated $6.5M sold.
Based on aggregated 13F filings for Q4 2020.